Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Daniel Couriel(University of Utah), Attaphol Pawarode(University of Michigan), Patrick J. Stiff(Loyola University Medical Center), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Roger Strair(Johnson University), Horatiu Olteanu(Mayo Clinic in Arizona), Amanda F. Cashen(Washington University in St. Louis), Emmanuel Katsanis(University of Arizona), Rachel B. Salit(Johns Hopkins Hospital), Monzr M. Al Malki(City of Hope), Alessandro Digilio, José L. Díez‐Martín(Universidad Complutense de Madrid), Nelson Hamerschlak(Hospital Israelita Albert Einstein), Richard A. Nash(Colorado Blood Cancer Institute), Yulia Linhares(Cedars-Sinai Medical Center), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Timothy S. Fenske(Medical College of Wisconsin), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Amir Steinberg(New York Medical College), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Eric D. Jacobsen(Dana-Farber Cancer Institute), Bipin N. Savani(Vanderbilt University Medical Center), Shahram Mori(Florida Hospital Cancer Institute), Carol M. Richman(University of California, Davis), Michael Y. Shapira(Hebrew University of Jerusalem), Colin Phipps(Singapore General Hospital), Kwang Woo Ahn(Medical College of Wisconsin), Edward D. Ball(Sheba Medical Center), Sonali M. Smith(University of Chicago)
Cited by 72
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k